Panaji Journal

Epilepsy Drugs Market, Impact of COVID-19, By Drugs Category, Country, Companies, Forecast by 2027 – Renub Research

 Breaking News
  • No posts were found

Epilepsy Drugs Market, Impact of COVID-19, By Drugs Category, Country, Companies, Forecast by 2027 – Renub Research

September 01
12:25 2021
Epilepsy Drugs Market, Impact of COVID-19, By Drugs Category, Country, Companies, Forecast by 2027 - Renub Research
According to this research report, the Global Epilepsy Drugs Industry is likely to grow at a CAGR of 5.46% during (2020- 2027).
Epilepsy Drugs Market is projected to reach US$ 10.3 Billion by 2027. Global Forecast, Impact of COVID-19, Industry Trends, by Drugs Category, Country, Growth, Opportunity Company Analysis.

Globally, millions of people are affected by neurological disorders. In that, over 80% of the death takes place in the low and middle-income countries. Worldwide Epilepsy is the most common neurological disorder, affecting people of all ages. This disease is a chronic brain disorder characterized by sudden and recurrent episodes of seizure. Patients who have epilepsy suffer from sudden behavioral changes, loss of consciousness and severe emotional distress. According to the World Health Organization (WHO), around 50 million people have epilepsy worldwide. Epilepsy is a common serious, and about 2.4 million new cases are diagnosed annually.

 

Besides, the rising incidence of higher birth-related injuries, neurological disorders, increasing road traffic injuries, growing disease awareness, and rising patient base in developing countries are the significant factors driving the global Epilepsy drug market. Increasing R&D investment and the launch of extended-release formulations are further expected to fuel the market growth. According to Renub Research, the Global Epilepsy Drugs Market is projected to reach US$ 10.3 Billion by 2027.

 

Globally, United States is the largest epilepsy drug market due to better healthcare infrastructure and rising cases of epilepsy. As per the Epilepsy Foundation of Michigan, epilepsy is the fourth most common neurological disorder in the United States after stroke, migraine, and Alzheimer’s disease. About one percent of Americans have some form of epilepsy, and nearly four percent (which is equal to 1 in 26) will develop epilepsy at some point in their lives. Thus, there is a rising demand for effective treatment in the US, significantly boosting the growth of the epilepsy drug market.

 

Request a Free Sample Copy of the Report: https://www.renub.com/request-sample-page.php?gturl=epilepsy-drugs-market-p.php

 

Additionally, China, India, and Brazil were among the countries with a higher proportion of the population suffering from the condition. To minimize the burden of this disease and facilitate the availability of better treatment options, governments from various countries across the world are providing active support. According to this research report, the Global Epilepsy Drugs Industry is likely to grow at a CAGR of 5.46% during (2020- 2027).

 

Based on Drugs Category

The global epilepsy drugs market is segmented into First Generation, Second Generation, Third Generation, Others. The third Generation holds the largest market share; the major factors responsible for the growth of the third generation segment include the launch of highly efficacy drugs with the enhanced mechanism of action, fewer side effects and the awaited launch of new pipeline medicines. Third-generation drugs such as Vimpat, Briviact and others have penetrated the worldwide market considerably and proven to be quite effective in treating epilepsy.

 

On the other hand, the second-generation antiepileptic drug class, including Keppra, Fycompa and Briviact. They dominated the market due to their large tolerability and safety due to the launch of highly potent drugs, which apply novel techniques mechanisms of action. Worldwide Epilepsy Drugs Market Size was US$ 7.1 Billion in 2020.

 

Top players such as Eisai Co., Ltd., UCB Inc., H. Lundbeck A/S, and GW Pharmaceuticals Plc. of Epilepsy Drugs Market focus on introducing medications that have lesser side-effects to the patients. Besides, companies are also focused on improving the potentiality of the drugs to control the symptoms of epilepsy effectively. In 2020, Eisai Co., Ltd. announced the launch of FYCOMPA in China to treat patients aged 12 years and more adults with partial-onset seizures.

 

Renub Research latest report “Global Epilepsy Drugs Market by Country (United States, United Kingdom, France, Germany, Italy, Spain, India, China, Japan) by Drugs Category (First Generation, Second Generation, Third Generation and Others) by Drugs (Vimpat (Lacosamide), Keppra (Levetiracetam), Sabril (Vigabatrin), Onfi (Clobazam), Fycompa Briviact (Brivaracetam), Epidiolex, Cenobamate (YKP3089) and Others) Company Analysis (Eisai Co., Ltd., UCB Inc., H. Lundbeck A/S, GW Pharmaceuticals Plc.)” Provides a detailed analysis Global Epilepsy Drugs Industry.

 

Follow the link for the full report with detailed TOC and list of figures and tables: https://www.renub.com/epilepsy-drugs-market-p.php

 

Country – Global Epilepsy Drugs Market have been covered from 9 Viewpoints: 

   1.    United States

   2.    United Kingdom

   3.    France

   4.    Germany

   5.    Italy

   6.    Spain

   7.    India

   8.    China

   9.    Japan

 

Drugs Category – Global Epilepsy Drugs Market have been covered from 4 Viewpoints: 

   1.    First Generation

   2.    Second Generation

   3.    Third Generation

   4.    Others

 

Drugs – Global Epilepsy Drugs Market have been covered from 9 Viewpoints:

   1.    Vimpat (Lacosamide)

   2.    Keppra (Levetiracetam)

   3.    Sabril (Vigabatrin)

   4.    Onfi (Clobazam)

   5.    Fycompa

   6.    Briviact (Brivaracetam)

   7.    Epidiolex

   8.    Cenobamate (YKP3089)

   9.    Others

 

Company Insights:

   •    Overview

   •    Company Initiatives

   •    Sales Analysis

 

Companies Covered:

   1.    Eisai Co., Ltd.

   2.    UCB Inc.

   3.    H. Lundbeck A/S

   4.    GW Pharmaceuticals Plc.

 

Industry Related Reports:

Netherlands Diabetes Market: https://www.renub.com/netherlands-diabetes-market-p.php

Diabetes Drug Market: https://www.renub.com/diabetes-drug-market-p.php

 

About the Company: 

Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food & Beverages, Power & Energy, Information Technology, Telecom & Internet, Chemical, Logistics & Automotive, Consumer Goods & Retail, Building, and Construction, & Agriculture. Our clients rely on our market analysis and data to make informed knowledgeable decisions. We are regarded as one of the best providers of knowledge. Our pertinent analysis helps consultants, bankers, and executives to make informed and correct decisions.

Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more. Our research helps to make business decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We support many blue chip companies by providing them with findings and perspectives across a wide range of markets. Our research reports offer a blend of information insight, analysis, and forecasting that is essential in today’s ultra-competitive markets.

 

Contact Us:

Renub Research

Phone No: +1 678-302-0700 (USA) | +91–120–421–9822 (IND)

Email: info[at]renub[dot]com

Web: https://www.renub.com

Follow on Linkedin: https://www.linkedin.com/company/renub-research

Media Contact
Company Name: Renub Research
Contact Person: Rajat Gupta
Email: Send Email
Phone: 16783020700
Address:Roswell, GA 30076
City: Roswell
State: GA
Country: United States
Website: www.renub.com/drugs-and-pharmaceuticals-13-c.php

Related Articles